R&G PharmaStudies Co., Ltd. (SHE:301333)
China · Delayed Price · Currency is CNY 78.07
-0.28 (-0.36%)
At close: Feb 12, 2026
R&G PharmaStudies Market Cap
R&G PharmaStudies has a market cap or net worth of 7.2 billion as of February 13, 2026. Its market cap has increased by 63.00% in one year.
Market Cap
7.20B
Enterprise Value
5.49B
Revenue
789.45M
Ranking
n/a
PE Ratio
47.56
Stock Price
78.07
Market Cap Chart
Since August 2, 2022, R&G PharmaStudies's market cap has increased from 5.40B to 7.20B, an increase of 33.32%. That is a compound annual growth rate of 8.47%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Feb 13, 2026 | 7.20B | 27.09% |
| Dec 31, 2025 | 5.67B | 19.12% |
| Dec 31, 2024 | 4.76B | -23.17% |
| Dec 29, 2023 | 6.19B | 25.30% |
| Dec 30, 2022 | 4.94B | -8.52% |
| Aug 2, 2022 | 5.40B | - |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Nanjing Vazyme Biotech | 8.26B |
| Zhejiang Ausun Pharmaceutical | 8.05B |
| Suzhou Fengbei Biotech Stock | 7.86B |
| Wuhan Keqian Biology Co.,Ltd | 7.53B |
| Jiangsu Aidea Pharmaceutical Group | 7.36B |
| Shenzhen Weiguang Biological Products | 7.00B |
| GemPharmatech | 6.98B |
| Shanghai OPM Biosciences | 6.85B |